An integrated catalytic decarboxylation/carboxylation for accessing isotopically labeled carboxylic acids with 13 CO 2 or 14 CO 2 is described. The method shows a wide scope under mild conditions, even in the context of late-stage functionalization, and does not require stoichiometric organometallics, thus complementing existing carbon-labeling techniques en route to carboxylic acids.
T he evaluation of the metabolic profile of lead compounds through preclinical testing is of utmost importance in drug discovery. 1 Although these studies require isotopically labeled active pharmaceutical ingredients (APIs), their synthesis is oftentimes more problematic than that of the parent compound, reinforcing the need for strategies that rapidly and reliably incorporate isotopes into molecules. 2 Among different scenarios, carbon labeling is often preferred due to its high sensitivity and lower risk of label metabolic cleavage, rendering the interpretation of preclinical data easy. 3 While 11 C is utilized for positron emitting tomography (PET) imaging, 4 its short half-life precludes long-term studies. However, 13 C-and 14 Clabeling are appropriate for evaluating drug profiles, including absorption, distribution, metabolism, and excretion (ADME), and pharmacokinetic studies (Scheme 1). 5, 6 Although radioactive 14 C has oftentimes displaced 13 C as metabolic tracers, recent advances in mass spectrometry and nuclear magnetic resonance have allowed the latter to be used for similar purposes, 7 thus improving the practicality of these studies by employing stable 13 C probes.
Prompted by the prevalence of carboxylic acids in biologically active molecules (Scheme 1, bottom), 8 carboxylation reactions with isotopically labeled CO 2 have attracted considerable attention. 9, 10 At present, high levels of 13 C-and 14 C-incorporation can be achieved with stoichiometric and polarized organometallics; 11 however, their high reactivity and low chemoselectivity severely limit the synthetic application of these processes (Scheme 2, top left). Although decarboxylation allows carbon isotopes of carboxylic acids in drug molecules to be rapidly interchanged without modifying the established route to the drug molecule (Scheme 2, top middle/right), 12 such techniques require stoichiometric nickel species 13a or harsh conditions. 13b In addition, modest C-labeling exchange is observed due to competitive hydrolysis of the starting precursor or in situ carboxylation with initially extruded 12 CO 2 . 13 Taken together, these features contribute to the perception that designing a mild, robust, and modular catalytic decarboxylation/carboxylation that enables the access to Clabeled aliphatic and aromatic carboxylic acids in high specific activities is deemed necessary. As part of our interest in catalytic carboxylation reactions, 14 we report the successful realization of a catalytic carbon isotope exchange by merging decarboxylative events with carboxylation protocols with 13 CO 2 or 14 CO 2 via the intermediacy of halogenated species or activated esters (Scheme 2, bottom). Our protocols are distinguished by their mild conditions, versatility, excellent chemoselectivity profile, and high isotopic incorporations (up to >99% C-labeling), thus expediting the design of radiolabeling techniqueseven in the context of late-stage functionalizationen route to labeled carboxylic acids while obviating the need for stoichiometric organometallic species.
Our investigations began by evaluating the feasibility of the approach highlighted in Scheme 2 (bottom) with easy-tohandle 13 CO 2 in lieu of radioactive 14 CO 2 and the Nhydroxyphthalimido ester 1a, readily available in a single step from octanoic acid. 15 A judicious optimization of all reaction parameters revealed that a combination of NiCl 2 ·dme (10 mol %) and 6,6′-dimethyl-4,4′-diphenyl-2,2′-bipyridine L1 (25 mol %) in DMF:MeOH (3:1) at 0°C with Mn as reducing agent under an atmospheric pressure of 13 CO 2 provided the best results, affording [ 13 C]2a in 55% yield and 56% 12 C/ 13 Cexchange. 15 In line with our expectations, bipyridine and phenanthroline ligands possessing substituents adjacent to the nitrogen atom were critical for success. 16 Indeed, the absence of the latter resulted in negligible conversions, if any, to [ 13 C]2a, thus showing the structural intricacies on the ligand backbone. Likewise, solvents and reducing agents other than DMF:MeOH or Mn had a deleterious effect on reactivity and specificity, whereas control experiments revealed that all reaction parameters were essential for the catalytic carboxylation to occur. 15 With a set of conditions in hand, we turned our attention to study the generality of our Ni-catalyzed decarboxylative/ carboxylation of N-hydroxyphthalimido esters. As shown in Table 1 , an array of linear (2a−2f, 2i−2m) or α-branched (2g, 2h) labeled carboxylic acids could easily be within reach from their parent analogues. The chemoselectivity of our 12 C/ 13 Ccarbon-labeling exchange posed no problems, as nitriles (2i), alkenes (2j), carbamates (2m), or nitrogen-containing heterocycles (2d) could all be well-accommodated. Interestingly, not even traces of competitive Ni-catalyzed carboxylation at the C−Cl terminus was observed in 2b and 2k, 17 thus leaving ample room for further functionalization via conventional cross-coupling reactions. 18 Particularly noteworthy was the ability to enable the targeted 12 C/ 13 C-exchange at late-stages with advanced carboxylic acid intermediates such as citronellic acid (2j), MCPB (2k), lithocholic acid (2l), or pregabalin (2m), thus showing the potential that our catalytic protocol might have in preclinical studies for drug discovery. 19 Putting these results into perspective, the examples shown in Table 1 represent a powerful alternative to existing methodologies based on the utilization of stoichiometric amounts of organometallics 11 or Ni complexes. 13a The data shown in Scheme 3 (top) illustrates the prospective impact of our 12 C/ 13 C-exchange by converting 3a and 3b into their [ 13 C]5a and [ 13 C]5b congeners without chromatographic purification. 15 However, a number of daunting challenges remain. Among these, a seemingly trivial extension to 13 C-labeled phenyl acetic acids or benzoic acids events still constitutes terra incognita; substantial homodimerization is observed in the former whereas a difficult decarboxylation of aryl NHP-esters prevents a 12 C/ 13 Cexchange in the latter. More importantly, modest isotope exchange was observed for all substrates shown in Table 1 due to unavoidable hydrolysis of the parent NHP-ester and competitive carboxylation with 12 CO 2 . These observations are particularly problematic due to the prevalence of carboxylic acids in APIs as well as the need for maximizing the 12 C/ 13 Cexchange for preclinical testing. To this end, we anticipated that the merger of decarboxylative halogenation with the robustness of catalytic carboxylation of organic halides might offer a powerful platform for obtaining otherwise inaccessible carboxylic acids with >99% 13 C-content. As shown in Scheme Scheme 2. 13 C]5b in slightly lower overall yields to those shown for NHP-esters but with >99% 13 C-labeling. Encouraged by these results, we examined the 13 C-carboxylation of a host of benzyl, aryl, or unactivated alkyl chlorides obtained via decarboxylative halogenation of the parent carboxylic acids (Table 2) . Notably, nitriles (5c), esters (5d−5f), or nitrogen-containing heterocycles (5e) do not interfere, obtaining in all cases >99% 13 Clabeling. Albeit in lower yields, secondary and tertiary alkyl carboxylic acids such as 5b, 5g, or 5h were within reach, with 5g being obtained as a single diastereoisomer. Importantly, 13 C-labeled aryl acetic acids (5i, 5j) and (hetero)aryl carboxylic acids (5k−5m)compounds that were beyond reach from NHP-esterscould also be coupled under Ni/ neocuproine or Ni/PPh 3 regimes, thus representing an opportunity to improve upon existing C-labeling techniques. Aimed at extending the applicability of our carbon isotope exchange, we next focused our attention on converting αbranched carboxylic acids into their labeled linear analogues via chain-walking scenarios, 14a,21 a transformation that has proven elusive in related labeling approaches. 13a Although in low yields, the preparation of [ 13 C]2a,5a,6 with >99% 13 Clabeling not only demonstrates the successful realization of this goal (Scheme 4) but also sets the basis for designing siteselective radiolabeling techniques at remote sp 3 C−H sites. 22 Given the key role of 14 C-radiolabeling in pharmacokinetic and ADME studies, 5 the ability to access 14 C-labeled molecules was then explored. Preliminary results successfully highlighted the applicability of this method under otherwise similar conditions. 15 It is particularly noteworthy that [ 14 C]5i and [ 14 C]5k are obtained in high molar activities (≥2.04 GBq mmol −1 ) 23 with negligible isotope dilution, thus opening a gateway to study the metabolic activity of drugs containing carboxylic acid motifs.
In conclusion, we have developed a simple, efficient, and highly versatile catalytic decarboxylation/carboxylation for carbon isotope exchange of carboxylic acids with 13 CO 2 or 14 CO 2 . This route enables access to labeled aliphatic or aromatic carboxylic acids, even at late-stages, without changing the already established sequence en route to the parent compound, thus offering a robust and economical gateway for rapidly and reliably obtaining preclinical data for lead Scheme 3. Direct 12 C/ 13 C-Exchange of Carboxylic Acids a a Ni/L1, Table 1 ; Ni/L2, NiBr 2 ·dme (10 mol %), L2 (24 mol %), Mn (2 equiv), TBAB (1 equiv), 13 Author Contributions ⊥ Y.D., B.S., F.C., and G.T. contributed equally.
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